XKd Efficacy (as of 22 April 2021)

Summary and Conclusions

The RP2D of XKd with continuous weekly selinexor is once-weekly selinexor 80 mg + carfilzomib 56 mg/m² + dexamethasone 40 mg

The combination is highly active and durable with a PFS of 15 months and an ORR of 78.1%, with deep responses (≥ VGPR) in 40.7% of patients who had a median of 4 times of prior therapy

The most common TRAEs are thrombocytopenia, nausea, anemia, fatigue and anorexia which are expected and can be managed with supportive care and/or dose modifications

Further exploration with selinexor dosing on days 1, 8 and 15 is 28 days is ongoing; currently recommended dosing is selinexor 80 mg (days 1, 8, 15) + carfilzomib 56 mg/m² (days 1, 8, 21) + dexamethasone 40 mg QD of 28-day cycles

Acknowledgments

Patients, their families, and caregivers Investigators, co-investigators, and study team at each institution

This study was supported by Karyopharm Therapeutics.